ArticleRadiology2022
Artificial Intelligence Tool for Assessment of Indeterminate Pulmonary Nodules Detected with CT.
Registry-linked trialOpen access · greenAbstract read
In one paragraph
Article in Radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05968898 (Assessment of a Radiomics-based Computer-Aided Diagnosis Tool for Cancer Risk Stratification of Pulmonary Nodules), which is not on this map. Cited by 48 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 2 pooled it
10.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assessment of a Radiomics-based Computer-Aided Diagnosis Tool for Cancer Risk Stratification of Pulmonary Nodules
Who cites it
48 citing papers in PubMed, 2 syntheses or guidelines pooled it, 71 citations in OpenAlex.
- Lung cancer screening with low-dose CT: definition of positive, indeterminate, and negative screen results. A nodule management recommendation from the European Society of Thoracic Imaging.European radiology · 2026Guideline
- Pooled it
- Improving the efficiency of identifying malignant pulmonary nodules before surgery via a combination of artificial intelligence CT image recognition and serum autoantibodies.European radiology · 2023Trial
- Has computer-aided diagnosis now outperformed radiologists in the accurate localization of lung nodules?-a multicenter retrospective study.Quantitative imaging in medicine and surgery · 2026Article
- Scientific evidence of commercial artificial intelligence products for pulmonary nodule assessment on CT scans: a systematic review.European radiology · 2026Article
- Recent advances in artificial intelligence across interventional pulmonology: a narrative review.Journal of thoracic disease · 2026Review
- Biomarkers for Lung Nodule Risk Stratification: Are We There Yet?Diagnostics (Basel, Switzerland) · 2026Review
- Theoretical Clinical Utility of Advanced Practice Provider Use of an Artificial Intelligence Radiomics-based Tool for Pulmonary Nodule Evaluation and Management.CHEST pulmonary · 2026Article
- Article
- DeepFAN, a transformer-based model for human-artificial intelligence collaborative assessment of incidental pulmonary nodules in CT scans: a multireader, multicase trial.Nature cancer · 2026Article
- The role of radiological imaging in differentiating malignant and benign pulmonary nodules: a retrospective study.BMC medical imaging · 2026Article
- Clinicians' cancer risk assessment among patients with pulmonary nodules: a qualitative study.Annals of the American Thoracic Society · 2026Article
- Article
- Cost-effectiveness analysis of artificial intelligence-assisted risk stratification of indeterminate pulmonary nodules.PloS one · 2026Article
- Assessing Invasiveness of Ground-Glass Nodules Using Ternary-Class CT Radiomics Models: A Multi-Center Study with SHAP Explanations.Cancer management and research · 2026Article
- Performance of a screening-trained DL model for pulmonary nodule malignancy estimation of incidental clinical nodules.European radiology · 2026Article
- Evaluating the diagnostic performance of artificial intelligence-assisted decision-making software for pulmonary nodules in a resource-limited setting.Journal of clinical imaging science · 2026Article
- Aggressiveness-guided nodule management for lung cancer screening in Europe-justification for follow-up intervals and definition of growth.European radiology · 2026Review
- Preoperative CT-based artificial intelligence-derived quantitative parameters and imaging features for predicting the invasiveness of histologically confirmed subcentimeter adenocarcinomatous nodules: a two-center study.Quantitative imaging in medicine and surgery · 2025Article
- Employment of artificial intelligence for early lung cancer diagnosis: a retrospective cohort study.BMJ open respiratory research · 2025Article
Corrections and comments
- Commented on by
Authors and funding
12 authors at 3 institutions in 2 countries.
Roger Y KimFrom the Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Suite 216, Stemmler Hall, 3450 Hamilton Walk, Philadelphia, PA 19104 (R.Y.K., A.V.); Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom (J.L.O.); Optellum, Oxford, United Kingdom (L.C.P.); Department of Radiology and Radiological Science, Medical University of South Carolina, Charleston, SC (R.F.M.); Department of Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine, Winston-Salem, NC (T.L.D., C.R.B.); Division of Pulmonary and Critical Care Medicine, Department of Medicine, Henry Ford Health System, Detroit, Mich (A.C., M.J.S.); Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt Ingram Cancer Center, Nashville, Tenn (P.P.M.); and Department of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom (C.F., F.V.G.).ORCID 0000-0002-8262-484X
Jason L OkeFrom the Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Suite 216, Stemmler Hall, 3450 Hamilton Walk, Philadelphia, PA 19104 (R.Y.K., A.V.); Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom (J.L.O.); Optellum, Oxford, United Kingdom (L.C.P.); Department of Radiology and Radiological Science, Medical University of South Carolina, Charleston, SC (R.F.M.); Department of Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine, Winston-Salem, NC (T.L.D., C.R.B.); Division of Pulmonary and Critical Care Medicine, Department of Medicine, Henry Ford Health System, Detroit, Mich (A.C., M.J.S.); Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt Ingram Cancer Center, Nashville, Tenn (P.P.M.); and Department of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom (C.F., F.V.G.).
Lyndsey C PickupFrom the Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Suite 216, Stemmler Hall, 3450 Hamilton Walk, Philadelphia, PA 19104 (R.Y.K., A.V.); Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom (J.L.O.); Optellum, Oxford, United Kingdom (L.C.P.); Department of Radiology and Radiological Science, Medical University of South Carolina, Charleston, SC (R.F.M.); Department of Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine, Winston-Salem, NC (T.L.D., C.R.B.); Division of Pulmonary and Critical Care Medicine, Department of Medicine, Henry Ford Health System, Detroit, Mich (A.C., M.J.S.); Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt Ingram Cancer Center, Nashville, Tenn (P.P.M.); and Department of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom (C.F., F.V.G.).
Reginald F MundenFrom the Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Suite 216, Stemmler Hall, 3450 Hamilton Walk, Philadelphia, PA 19104 (R.Y.K., A.V.); Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom (J.L.O.); Optellum, Oxford, United Kingdom (L.C.P.); Department of Radiology and Radiological Science, Medical University of South Carolina, Charleston, SC (R.F.M.); Department of Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine, Winston-Salem, NC (T.L.D., C.R.B.); Division of Pulmonary and Critical Care Medicine, Department of Medicine, Henry Ford Health System, Detroit, Mich (A.C., M.J.S.); Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt Ingram Cancer Center, Nashville, Tenn (P.P.M.); and Department of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom (C.F., F.V.G.).
Travis L DotsonFrom the Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Suite 216, Stemmler Hall, 3450 Hamilton Walk, Philadelphia, PA 19104 (R.Y.K., A.V.); Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom (J.L.O.); Optellum, Oxford, United Kingdom (L.C.P.); Department of Radiology and Radiological Science, Medical University of South Carolina, Charleston, SC (R.F.M.); Department of Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine, Winston-Salem, NC (T.L.D., C.R.B.); Division of Pulmonary and Critical Care Medicine, Department of Medicine, Henry Ford Health System, Detroit, Mich (A.C., M.J.S.); Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt Ingram Cancer Center, Nashville, Tenn (P.P.M.); and Department of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom (C.F., F.V.G.).
Christina R BellingerFrom the Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Suite 216, Stemmler Hall, 3450 Hamilton Walk, Philadelphia, PA 19104 (R.Y.K., A.V.); Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom (J.L.O.); Optellum, Oxford, United Kingdom (L.C.P.); Department of Radiology and Radiological Science, Medical University of South Carolina, Charleston, SC (R.F.M.); Department of Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine, Winston-Salem, NC (T.L.D., C.R.B.); Division of Pulmonary and Critical Care Medicine, Department of Medicine, Henry Ford Health System, Detroit, Mich (A.C., M.J.S.); Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt Ingram Cancer Center, Nashville, Tenn (P.P.M.); and Department of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom (C.F., F.V.G.).
Avi CohenFrom the Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Suite 216, Stemmler Hall, 3450 Hamilton Walk, Philadelphia, PA 19104 (R.Y.K., A.V.); Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom (J.L.O.); Optellum, Oxford, United Kingdom (L.C.P.); Department of Radiology and Radiological Science, Medical University of South Carolina, Charleston, SC (R.F.M.); Department of Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine, Winston-Salem, NC (T.L.D., C.R.B.); Division of Pulmonary and Critical Care Medicine, Department of Medicine, Henry Ford Health System, Detroit, Mich (A.C., M.J.S.); Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt Ingram Cancer Center, Nashville, Tenn (P.P.M.); and Department of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom (C.F., F.V.G.).
Michael J SimoffFrom the Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Suite 216, Stemmler Hall, 3450 Hamilton Walk, Philadelphia, PA 19104 (R.Y.K., A.V.); Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom (J.L.O.); Optellum, Oxford, United Kingdom (L.C.P.); Department of Radiology and Radiological Science, Medical University of South Carolina, Charleston, SC (R.F.M.); Department of Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine, Winston-Salem, NC (T.L.D., C.R.B.); Division of Pulmonary and Critical Care Medicine, Department of Medicine, Henry Ford Health System, Detroit, Mich (A.C., M.J.S.); Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt Ingram Cancer Center, Nashville, Tenn (P.P.M.); and Department of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom (C.F., F.V.G.).ORCID 0000-0001-9192-5647
Pierre P MassionFrom the Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Suite 216, Stemmler Hall, 3450 Hamilton Walk, Philadelphia, PA 19104 (R.Y.K., A.V.); Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom (J.L.O.); Optellum, Oxford, United Kingdom (L.C.P.); Department of Radiology and Radiological Science, Medical University of South Carolina, Charleston, SC (R.F.M.); Department of Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine, Winston-Salem, NC (T.L.D., C.R.B.); Division of Pulmonary and Critical Care Medicine, Department of Medicine, Henry Ford Health System, Detroit, Mich (A.C., M.J.S.); Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt Ingram Cancer Center, Nashville, Tenn (P.P.M.); and Department of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom (C.F., F.V.G.).
Claire FilippiniFrom the Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Suite 216, Stemmler Hall, 3450 Hamilton Walk, Philadelphia, PA 19104 (R.Y.K., A.V.); Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom (J.L.O.); Optellum, Oxford, United Kingdom (L.C.P.); Department of Radiology and Radiological Science, Medical University of South Carolina, Charleston, SC (R.F.M.); Department of Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine, Winston-Salem, NC (T.L.D., C.R.B.); Division of Pulmonary and Critical Care Medicine, Department of Medicine, Henry Ford Health System, Detroit, Mich (A.C., M.J.S.); Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt Ingram Cancer Center, Nashville, Tenn (P.P.M.); and Department of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom (C.F., F.V.G.).ORCID 0000-0003-0727-8294
Fergus V GleesonFrom the Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Suite 216, Stemmler Hall, 3450 Hamilton Walk, Philadelphia, PA 19104 (R.Y.K., A.V.); Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom (J.L.O.); Optellum, Oxford, United Kingdom (L.C.P.); Department of Radiology and Radiological Science, Medical University of South Carolina, Charleston, SC (R.F.M.); Department of Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine, Winston-Salem, NC (T.L.D., C.R.B.); Division of Pulmonary and Critical Care Medicine, Department of Medicine, Henry Ford Health System, Detroit, Mich (A.C., M.J.S.); Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt Ingram Cancer Center, Nashville, Tenn (P.P.M.); and Department of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom (C.F., F.V.G.).ORCID 0000-0002-5121-3917
Anil VachaniFrom the Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Suite 216, Stemmler Hall, 3450 Hamilton Walk, Philadelphia, PA 19104 (R.Y.K., A.V.); Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom (J.L.O.); Optellum, Oxford, United Kingdom (L.C.P.); Department of Radiology and Radiological Science, Medical University of South Carolina, Charleston, SC (R.F.M.); Department of Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine, Winston-Salem, NC (T.L.D., C.R.B.); Division of Pulmonary and Critical Care Medicine, Department of Medicine, Henry Ford Health System, Detroit, Mich (A.C., M.J.S.); Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt Ingram Cancer Center, Nashville, Tenn (P.P.M.); and Department of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom (C.F., F.V.G.).ORCID 0000-0002-3871-8697
University of Oxford · GBHenry Ford Health System · USMedical University of South Carolina · US
Funding
Translational Research Support CoreP30ES013508 · NIEHS · UNIVERSITY OF PENNSYLVANIA · PI Trevor M Penning · 2006 to 2026
$35.3MCardiology & pulmonary research training grantT32HL007891 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI Jason D Christie · 1998 to 2026
$12.0MNHLBI NIH HHS T32 HL007891NIEHS NIH HHS P30 ES013508
Abstract
Background Limited data are available regarding whether computer-aided diagnosis (CAD) improves assessment of malignancy risk in indeterminate pulmonary nodules (IPNs). Purpose To evaluate the effect of an artificial intelligence-based CAD tool on clinician IPN diagnostic performance and agreement for both malignancy risk categories and management recommendations. Materials and Methods This was a retrospective multireader multicase study performed in June and July 2020 on chest CT studies of IPNs. Readers used only CT imaging data and provided an estimate of malignancy risk and a management recommendation for each case without and with CAD. The effect of CAD on average reader diagnostic performance was assessed using the Obuchowski-Rockette and Dorfman-Berbaum-Metz method to calculate estimates of area under the receiver operating characteristic curve (AUC), sensitivity, and specificity. Multirater Fleiss κ statistics were used to measure interobserver agreement for malignancy risk and management recommendations. Results A total of 300 chest CT scans of IPNs with maximal diameters of 5-30 mm (50.0% malignant) were reviewed by 12 readers (six radiologists, six pulmonologists) (patient median age, 65 years; IQR, 59-71 years; 164 [55%] men). Readers' average AUC improved from 0.82 to 0.89 with CAD (
Indexed as
Lung NeoplasmsMultiple Pulmonary NodulesAgedArtificial IntelligenceFemaleHumansMaleRetrospective StudiesSensitivity and SpecificityTomography, X-Ray Computed
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT05968898ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.